Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Linda Lieberman

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Midwifery Today with International Midwife|November 13, 2004
The business of midwifery. Managed care--the philosophyLinda Lieberman
Midwifery Today with International Midwife|July 17, 2008
Negotiating with the insurer for fair paymentLinda Lieberman
Midwifery Today with International Midwife|August 30, 2007
The business of midwifery: the financial plan for commercial insuranceLinda Lieberman
Midwifery Today with International Midwife|April 24, 2007
The business of midwifery: the financial planLinda Lieberman
Midwifery Today with International Midwife|May 6, 2004
The business of midwifery. An introductionLinda Lieberman
Midwifery Today with International Midwife|January 18, 2005
The business of midwifery coding ILinda Lieberman
Midwifery Today with International Midwife|December 3, 2005
The business of midwifery: documentation for successLinda Lieberman
Midwifery Today with International Midwife|October 12, 2007
The buisness of midwifery: practice design ILinda Lieberman
Midwifery Today with International Midwife|July 19, 2005
The business of midwifery: the federal registerLinda Lieberman
Neurology|March 16, 2017
CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients. Author ResponseEllen Cahir-McFarland, Richard M Ransohoff, Linda Lieberman, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Midwifery Today with International Midwife|November 13, 2004
The business of midwifery. Managed care--the philosophyLinda Lieberman
Midwifery Today with International Midwife|July 17, 2008
Negotiating with the insurer for fair paymentLinda Lieberman
Midwifery Today with International Midwife|August 30, 2007
The business of midwifery: the financial plan for commercial insuranceLinda Lieberman
Midwifery Today with International Midwife|April 24, 2007
The business of midwifery: the financial planLinda Lieberman
Midwifery Today with International Midwife|May 6, 2004
The business of midwifery. An introductionLinda Lieberman
Midwifery Today with International Midwife|January 18, 2005
The business of midwifery coding ILinda Lieberman
Midwifery Today with International Midwife|December 3, 2005
The business of midwifery: documentation for successLinda Lieberman
Midwifery Today with International Midwife|October 12, 2007
The buisness of midwifery: practice design ILinda Lieberman
Midwifery Today with International Midwife|July 19, 2005
The business of midwifery: the federal registerLinda Lieberman
Neurology|March 16, 2017
CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients. Author ResponseEllen Cahir-McFarland, Richard M Ransohoff, Linda Lieberman, et al.
Pageof 3